TABLE 2.
Severity, management and treatment features of COVID‐19 pneumonia (n = 47)
| Variable | Value |
|---|---|
| Severity of COVID‐19 pneumonia (based on CT Severity Score) | |
| Mild (total score) | 4 (8.5%) |
| Moderate (total score 8‐17) | 38 (80.9%) |
| Severe (total score ≥18) | 5 (10.6%) |
| Respiratory support | |
| Mechanical ventilation | 20 (42.6%) |
| Non‐invasive respiratory support | 18 (38.3%) |
| None | 9 (19.1%) |
| Corticosteroid usage for COVID‐19 treatment | |
| Intravenous (5 days) | 29 (61.7%) |
| Oral | 45 (95.7%) |
| Mean duration of administration | 7.7 ± 2.6 days |
| Anti‐viral therapy for COVID‐19 treatment | |
| None | 2 (4.3%) |
| Remdesivir only | 27 (57.4%) |
| Favipiravir only | 10 (21.3%) |
| Remdesivir & Favipiravir | 8 (17.0%) |
| Other immunomodulatory agents | |
| Tocilizumab | 1 (2.1%) |
| IVIg | 1 (2.1%) |
| Bevacizumab | 1 (2.1%) |